NewsF&O ban list 22 October 2026: Stocks in ban and MWPL watchlist, Manappuram Finance at 96.29%F&O ban list 22 October 2026: Stocks in ban and MWPL watchlist, Manappuram Finance at 96.29%
- Kaynes Technology India is in F&O ban with 101.88% MWPL utilisation, up 9.88 pp
- Manappuram Finance leads possible entrants at 96.29% MWPL utilisation
- Glenmark Pharmaceuticals saw the largest MWPL increase of 23.99 pp to 93.99%
- Crompton Greaves recorded the largest MWPL decrease of 5.58 pp to 81.42%
*this image is generated using AI for illustrative purposes only.
On October 22, 2026, three stocks are in F&O ban while Manappuram Finance tops the MWPL watchlist at 96.29%.
Stocks in F&O ban today
| # | Stock | Last close (₹) | Price change (%) | T-1 MWPL (%) | T-2 MWPL (%) | Change (pp) |
|---|---|---|---|---|---|---|
| 1 | Kaynes Technology India | 3,165.10 | -2.61 | 101.88 | 92.00 | +9.88 |
| 2 | Steel Authority of India | 169.50 | +0.31 | 93.93 | 94.00 | -0.07 |
| 3 | Ambuja Cements | 359.90 | -0.54 | 90.39 | 91.00 | -0.61 |
Kaynes Technology India recorded the highest utilisation among banned stocks at 101.88%, reflecting a 9.88 pp increase from the previous session. Steel Authority of India and Ambuja Cements saw minor decreases in MWPL utilisation, falling by 0.07 pp and 0.61 pp respectively.
Possible F&O ban entrants
| # | Stock | Last close (₹) | Price change (%) | T-1 MWPL (%) | T-2 MWPL (%) | Change (pp) |
|---|---|---|---|---|---|---|
| 1 | Manappuram Finance | 301.60 | -5.62 | 96.29 | 85.00 | +11.29 |
| 2 | LIC Housing Finance | 503.75 | -1.52 | 94.97 | 87.00 | +7.97 |
| 3 | Glenmark Pharmaceuticals | 2,194.10 | -0.73 | 93.99 | 70.00 | +23.99 |
| 4 | IREDA | 103.60 | -2.76 | 87.57 | 68.00 | +19.57 |
| 5 | Inox Wind | 62.62 | -3.50 | 84.18 | 87.00 | -2.82 |
| 6 | Crompton Greaves | 201.08 | -3.54 | 81.42 | 87.00 | -5.58 |
| 7 | Bandhan Bank | 159.10 | -2.87 | 78.82 | 81.00 | -2.18 |
| 8 | LIC of India | 392.05 | -0.33 | 78.21 | 78.00 | +0.21 |
| 9 | APL Apollo Tubes | 2,066.80 | -3.63 | 77.59 | 75.00 | +2.59 |
| 10 | Patanjali Foods | 357.00 | -2.14 | 76.98 | 73.00 | +3.98 |
Manappuram Finance holds the highest T-1 MWPL utilisation in the entrants list at 96.29%, which is above the 95% threshold. Glenmark Pharmaceuticals posted the largest increase with a 23.99 pp rise to 93.99%, while Crompton Greaves recorded the largest decrease, dropping 5.58 pp to 81.42%.
Possible entrants and recent developments
IREDA reported standalone net profit up 12% to ₹891.75 crore in H1FY27, with total income expanding 14% to ₹4,594.29 crore. The company's GNPA ratio improved to 3.57% while Net NPA declined to 1.08%.
Crompton Greaves uploaded its Q2FY27 earnings call recording on October 16, 2026, following a net profit rise of 65.1% YoY to ₹125 crore. Consolidated revenue grew 18.2% YoY to ₹2,263 crore. Separately, the company accepted the resignation of Compliance Officer Yesha Gandani effective October 16, 2026, and reassigned Nikhil Thakkar from Head of Internal Audit due to a new internal role.
LIC of India saw approximately 1,048,607 shares flagged in a large-trade signal on NSE on October 21, 2026, changing hands at ₹390.15 for a combined value of ₹40.91 crore.
Sector and MWPL change view
A majority of the supplied entrant names showed an increase in MWPL utilisation, led by significant jumps in Glenmark Pharmaceuticals and IREDA. Conversely, Crompton Greaves, Inox Wind, and Bandhan Bank recorded declines in their respective utilisation levels.
Understanding MWPL and the table
- MWPL is the maximum aggregate open interest permitted in a stock's derivatives.
- A stock enters the F&O ban when aggregate open interest exceeds 95% of MWPL; while it is in ban, participants may only reduce existing positions.
- Normal trading resumes when aggregate open interest falls to 80% of MWPL or below.
- T-1 is the latest completed trading session, T-2 is the preceding completed session, and Change (pp) is T-1 MWPL utilisation minus T-2 MWPL utilisation in percentage points.
How might the 11.29 percentage point surge in Manappuram Finance's MWPL utilisation impact liquidity for retail traders if it enters the F&O ban next session?
What specific institutional activities or corporate actions are driving the massive 23.99 pp jump in Glenmark Pharmaceuticals' derivatives open interest?
Will IREDA's improved asset quality metrics and profit growth sustain high derivative demand, or is the rising MWPL utilisation indicative of speculative overexposure?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
